Literature DB >> 33728076

Refractory Acute Interstitial Nephritis in the Setting of Nivolumab Therapy.

Antonio Faieta1, Tavis Dancik2.   

Abstract

A 65-year-old male patient with metastatic CCRCC developed steroid-dependent, grade 3 AIN secondary to nivolumab weeks after its initiation that resulted in 3 hospitalizations with acute renal failure. The patient was started on MM and his AIN was successfully controlled after a 2-year period of follow-up. Refractory renal AIN resulting from PD-1 inhibitor use is rare, and its successful treatment with mofetil mycophenolate with a 2-year follow-up in a patient with metastatic CCRCC has not been reported. This case is important because not only was his renal irAEs controlled but also long-term treatment with MM did not result in progression of metastatic disease.
Copyright © 2021 Antonio Faieta and Tavis Dancik.

Entities:  

Year:  2021        PMID: 33728076      PMCID: PMC7939740          DOI: 10.1155/2021/6640154

Source DB:  PubMed          Journal:  Case Rep Nephrol        ISSN: 2090-665X


  10 in total

Review 1.  Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review.

Authors:  Rimda Wanchoo; Sabine Karam; Nupur N Uppal; Valerie S Barta; Gilbert Deray; Craig Devoe; Vincent Launay-Vacher; Kenar D Jhaveri
Journal:  Am J Nephrol       Date:  2017-01-12       Impact factor: 3.754

2.  Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center.

Authors:  Troy Z Horvat; Nelly G Adel; Thu-Oanh Dang; Parisa Momtaz; Michael A Postow; Margaret K Callahan; Richard D Carvajal; Mark A Dickson; Sandra P D'Angelo; Kaitlin M Woo; Katherine S Panageas; Jedd D Wolchok; Paul B Chapman
Journal:  J Clin Oncol       Date:  2015-08-17       Impact factor: 44.544

3.  Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.

Authors:  Robert J Motzer; Bernard Escudier; David F McDermott; Saby George; Hans J Hammers; Sandhya Srinivas; Scott S Tykodi; Jeffrey A Sosman; Giuseppe Procopio; Elizabeth R Plimack; Daniel Castellano; Toni K Choueiri; Howard Gurney; Frede Donskov; Petri Bono; John Wagstaff; Thomas C Gauler; Takeshi Ueda; Yoshihiko Tomita; Fabio A Schutz; Christian Kollmannsberger; James Larkin; Alain Ravaud; Jason S Simon; Li-An Xu; Ian M Waxman; Padmanee Sharma
Journal:  N Engl J Med       Date:  2015-09-25       Impact factor: 91.245

4.  Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors.

Authors:  Frank B Cortazar; Kristen A Marrone; Megan L Troxell; Kenneth M Ralto; Melanie P Hoenig; Julie R Brahmer; Dung T Le; Evan J Lipson; Ilya G Glezerman; Jedd Wolchok; Lynn D Cornell; Paul Feldman; Michael B Stokes; Sarah A Zapata; F Stephen Hodi; Patrick A Ott; Michifumi Yamashita; David E Leaf
Journal:  Kidney Int       Date:  2016-06-07       Impact factor: 10.612

Review 5.  Nivolumab in the treatment of malignant melanoma: review of the literature.

Authors:  Emi Mashima; Akiha Inoue; Yumiko Sakuragi; Takashi Yamaguchi; Natsuko Sasaki; Yoko Hara; Daisuke Omoto; Shun Ohmori; Sanehito Haruyama; Yu Sawada; Manabu Yoshioka; Daisuke Nishio; Motonobu Nakamura
Journal:  Onco Targets Ther       Date:  2015-08-06       Impact factor: 4.147

6.  Acute interstitial nephritis related to immune checkpoint inhibitors.

Authors:  Julie Belliere; Nicolas Meyer; Julien Mazieres; Sylvie Ollier; Serge Boulinguez; Audrey Delas; David Ribes; Stanislas Faguer
Journal:  Br J Cancer       Date:  2016-11-10       Impact factor: 7.640

7.  Interstitial nephritis in melanoma patients secondary to PD-1 checkpoint inhibitor.

Authors:  Julia Escandon; Stephanie Peacock; Asaad Trabolsi; David B Thomas; Ayman Layka; Jose Lutzky
Journal:  J Immunother Cancer       Date:  2017-01-17       Impact factor: 13.751

8.  Acute interstitial nephritis after sequential ipilumumab - nivolumab therapy of metastatic melanoma.

Authors:  Lea Bottlaender; Anne-Laure Breton; Louis de Laforcade; Frederique Dijoud; Luc Thomas; Stephane Dalle
Journal:  J Immunother Cancer       Date:  2017-07-18       Impact factor: 13.751

Review 9.  Incidence of Immune-Related Adverse Events with Program Death Receptor-1- and Program Death Receptor-1 Ligand-Directed Therapies in Genitourinary Cancers.

Authors:  Benjamin L Maughan; Erin Bailey; David M Gill; Neeraj Agarwal
Journal:  Front Oncol       Date:  2017-04-03       Impact factor: 6.244

10.  Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience.

Authors:  Omar Mamlouk; Umut Selamet; Shana Machado; Maen Abdelrahim; William F Glass; Amanda Tchakarov; Lillian Gaber; Amit Lahoti; Biruh Workeneh; Sheldon Chen; Jamie Lin; Noha Abdel-Wahab; Jean Tayar; Huifang Lu; Maria Suarez-Almazor; Nizar Tannir; Cassian Yee; Adi Diab; Ala Abudayyeh
Journal:  J Immunother Cancer       Date:  2019-01-06       Impact factor: 13.751

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.